Supportive Oligonucleotide Technique (SOT) is a revolutionary and specialized treatment for chronic infections such as Lyme, EBV, HHV6, CMV, as well as cancer.
The patient’s blood is extracted and expedited to Greece to create personalized therapy.
Using the patient’s own cells, the therapy utilizes a specialized RNA known as a short interfering RNA (siRNAs) that binds to a specific gene, essential for the survival or replication of virus or cancer cells. These siRNAs block the expression of critical segments of genes needed for infections or cancer and thus disrupt cell replication. The SOT therapy is received at the clinic within 4-6 weeks of submission.
The SOT therapy is administered to the patient via an infusion that lasts about 45 minutes. The patient must take famotidine (Zantac) 30 minutes prior to the therapy to thwart any possible reaction. The SOT therapy will essentially act as a shut-off key preventing viruses and cancer from replicating. SOT has a long half-life and can ward off infection or cancer-replicating molecules for 3-4 months or longer. Studies show SOT has a high success rate with Leukemia (100%), Prostate Cancer (95%), Colorectal Cancer (88%), and Breast Cancer (81%). No adverse side effects were noted in the studies which suggests that patients of any age tolerate SOT therapy well.